|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000134215 |
Summary for VAV3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000134215 | Gene symbol | VAV3 |
| Gene name | vav guanine nucleotide exchange factor 3 | |
| HGNC | 12659 | |
| Entrez ID | 10451 | |
| Gene type | protein_coding | |
| Synonyms | VAV3| | |
| UniProtAcc | Q9UKW4 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for VAV3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| VAV3 | 6.64e+02 | -1.32e+00 | 1.78e-01 | -7.44e+00 | 9.96e-14 | 3.62e-11 | SARC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| VAV3 | 2.42e+03 | -1.10e+00 | 2.21e-01 | -4.98e+00 | 6.43e-07 | 2.46e-06 | HNSC |
| VAV3 | 1.58e+03 | 1.15e+00 | 2.52e-01 | 4.55e+00 | 5.25e-06 | 9.90e-06 | LUSC |
| VAV3 | 2.85e+03 | 1.75e+00 | 4.47e-01 | 3.93e+00 | 8.59e-05 | 3.90e-04 | BLCA |
| VAV3 | 1.25e+03 | 3.25e+00 | 7.04e-01 | 4.62e+00 | 3.79e-06 | 2.39e-05 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| VAV3 | 3.11e+02 | 1.10e+00 | 3.65e-01 | 3.01e+00 | 2.63e-03 | 6.03e-03 | LIHC |
| VAV3 | 1.08e+04 | 1.35e+00 | 1.23e-01 | 1.10e+01 | 4.93e-28 | 2.33e-27 | BRCA |
Top |
Sex-biased somatic mutation for VAV3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for VAV3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg01422262 | chr1:107963669 | CGI:chr1:107964629-107965419 | promoter,gene body | 3.62e-01 | 1.81e-01 | 2.19e+00 | 2.85e-02 | 3.16e-02 | 1.81e-01 |
| LUAD | cg12619536 | chr1:107965445 | CGI:chr1:107964629-107965419 | promoter | 1.56e-01 | 5.24e-02 | 2.83e+00 | 4.66e-03 | 7.06e-03 | 1.04e-01 |
| LUAD | cg05937496 | chr1:107965585 | CGI:chr1:107964629-107965419 | promoter | 1.49e-01 | 4.70e-02 | 4.64e+00 | 3.45e-06 | 1.79e-05 | 1.02e-01 |
| HNSC | cg06543087 | chr1:107965926 | CGI:chr1:107964629-107965419 | promoter | 2.55e-01 | 3.63e-02 | 3.74e+00 | 1.86e-04 | 4.36e-04 | 2.19e-01 |
| HNSC | cg19918758 | chr1:107965491 | CGI:chr1:107964629-107965419 | promoter | 1.85e-01 | 7.63e-02 | 2.42e+00 | 1.57e-02 | 1.88e-02 | 1.08e-01 |
| LUSC | cg05937496 | chr1:107965585 | CGI:chr1:107964629-107965419 | promoter | 1.39e-01 | 3.88e-02 | 4.02e+00 | 5.76e-05 | 5.76e-04 | 1.01e-01 |
| BLCA | cg12619536 | chr1:107965445 | CGI:chr1:107964629-107965419 | promoter | 1.59e-01 | 5.50e-02 | 2.13e+00 | 3.36e-02 | 3.67e-02 | 1.04e-01 |
| BLCA | cg19918758 | chr1:107965491 | CGI:chr1:107964629-107965419 | promoter | 1.79e-01 | 7.36e-02 | 2.25e+00 | 2.43e-02 | 2.85e-02 | 1.05e-01 |
| ESCA | cg01422262 | chr1:107963669 | CGI:chr1:107964629-107965419 | promoter,gene body | 5.14e-01 | 2.84e-01 | 2.56e+00 | 1.04e-02 | 3.64e-02 | 2.29e-01 |
| CHOL | cg06543087 | chr1:107965926 | CGI:chr1:107964629-107965419 | promoter | 2.42e-01 | 2.71e-02 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 2.15e-01 |
| CHOL | cg19753230 | chr1:107964190 | CGI:chr1:107964629-107965419 | promoter,gene body | 2.04e-01 | 4.82e-02 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 1.55e-01 |
| CHOL | cg17099397 | chr1:107965563 | CGI:chr1:107964629-107965419 | promoter | 3.97e-01 | 1.18e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 2.79e-01 |
| CHOL | cg05937496 | chr1:107965585 | CGI:chr1:107964629-107965419 | promoter | 1.77e-01 | 6.09e-02 | 2.51e+00 | 1.22e-02 | 2.39e-02 | 1.16e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg24662718 | chr1:107964846 | CGI:chr1:107964629-107965419 | promoter,exon,CDS,gene body | 2.48e-01 | 1.01e-01 | 2.35e+00 | 1.90e-02 | 2.49e-02 | 1.47e-01 |
| BLCA | cg01422262 | chr1:107963669 | CGI:chr1:107964629-107965419 | promoter,gene body | 3.04e-01 | 1.51e-01 | 2.29e+00 | 2.21e-02 | 2.89e-02 | 1.53e-01 |
| BLCA | cg25602490 | chr1:107964456 | CGI:chr1:107964629-107965419 | promoter,gene body | 2.18e-01 | 8.54e-02 | 2.18e+00 | 2.92e-02 | 3.48e-02 | 1.33e-01 |
| LIHC | cg25602490 | chr1:107964456 | CGI:chr1:107964629-107965419 | promoter,gene body | 1.77e-01 | 5.66e-02 | 2.44e+00 | 1.47e-02 | 1.88e-02 | 1.20e-01 |
| LIHC | cg05937496 | chr1:107965585 | CGI:chr1:107964629-107965419 | promoter | 2.14e-01 | 5.76e-02 | 2.79e+00 | 5.35e-03 | 8.47e-03 | 1.56e-01 |
Top |
Exon skipping events with PSI in TCGA for VAV3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for VAV3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for VAV3 |
| TFs related to VAV3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | AIRE | VAV3 | 3.99e+00 | 9.83e-01 | 2.50e+00 | 8.74e-04 | Male-biased |
| DLBC | BARX2 | VAV3 | 4.13e+00 | 9.87e-01 | 2.55e+00 | 6.53e-04 | Male-biased |
| DLBC | DLX3 | VAV3 | 4.43e+00 | 9.88e-01 | 3.32e+00 | 3.86e-03 | Male-biased |
| DLBC | DMRTA1 | VAV3 | 4.20e+00 | 9.88e-01 | 2.50e+00 | 4.54e-04 | Male-biased |
| DLBC | DMRTA2 | VAV3 | 4.21e+00 | 9.88e-01 | 2.56e+00 | 5.30e-04 | Male-biased |
| DLBC | E2F2 | VAV3 | 4.21e+00 | 9.81e-01 | 3.28e+00 | 7.32e-03 | Male-biased |
| DLBC | FOXD2 | VAV3 | 3.93e+00 | 9.82e-01 | 2.21e+00 | 4.21e-04 | Male-biased |
| DLBC | FOXP1 | VAV3 | 4.04e+00 | 9.83e-01 | 2.83e+00 | 2.44e-03 | Male-biased |
| DLBC | GBX1 | VAV3 | 4.53e+00 | 9.86e-01 | 3.61e+00 | 7.69e-03 | Male-biased |
| DLBC | GBX2 | VAV3 | 4.60e+00 | 9.91e-01 | 3.46e+00 | 3.47e-03 | Male-biased |
| DLBC | HMX2 | VAV3 | 4.30e+00 | 9.88e-01 | 3.11e+00 | 2.75e-03 | Male-biased |
| DLBC | HOXB7 | VAV3 | 3.94e+00 | 9.82e-01 | 2.50e+00 | 1.04e-03 | Male-biased |
| DLBC | HOXB8 | VAV3 | 4.11e+00 | 9.86e-01 | 2.75e+00 | 1.40e-03 | Male-biased |
| DLBC | IRF7 | VAV3 | 4.21e+00 | 9.84e-01 | 3.17e+00 | 4.82e-03 | Male-biased |
| DLBC | LBX2 | VAV3 | 4.68e+00 | 9.83e-01 | 3.88e+00 | 1.22e-02 | Male-biased |
| DLBC | LHX6 | VAV3 | 4.72e+00 | 9.92e-01 | 3.53e+00 | 2.75e-03 | Male-biased |
| DLBC | NKX3-1 | VAV3 | 4.15e+00 | 9.87e-01 | 2.28e+00 | 2.68e-04 | Male-biased |
| DLBC | PBX2 | VAV3 | 3.89e+00 | 9.80e-01 | 2.51e+00 | 1.30e-03 | Male-biased |
| DLBC | PDX1 | VAV3 | 4.14e+00 | 9.86e-01 | 2.79e+00 | 1.47e-03 | Male-biased |
| DLBC | POU3F1 | VAV3 | 4.71e+00 | 9.92e-01 | 3.53e+00 | 2.88e-03 | Male-biased |
| DLBC | POU3F3 | VAV3 | 3.99e+00 | 9.84e-01 | 1.88e+00 | 1.32e-04 | Male-biased |
| DLBC | POU3F4 | VAV3 | 4.82e+00 | 9.93e-01 | 3.67e+00 | 3.30e-03 | Male-biased |
| DLBC | SKOR1 | VAV3 | 4.14e+00 | 9.87e-01 | 2.62e+00 | 8.01e-04 | Male-biased |
| DLBC | SOX14 | VAV3 | 3.97e+00 | 9.82e-01 | 2.64e+00 | 1.57e-03 | Male-biased |
| DLBC | SOX15 | VAV3 | 4.13e+00 | 9.87e-01 | 2.61e+00 | 8.13e-04 | Male-biased |
| DLBC | SOX18 | VAV3 | 3.95e+00 | 9.82e-01 | 2.47e+00 | 9.12e-04 | Male-biased |
| DLBC | SOX2 | VAV3 | 4.04e+00 | 9.85e-01 | 2.48e+00 | 6.92e-04 | Male-biased |
| DLBC | SOX5 | VAV3 | 4.49e+00 | 9.92e-01 | 3.09e+00 | 1.25e-03 | Male-biased |
| DLBC | SRY | VAV3 | 4.07e+00 | 9.85e-01 | 2.49e+00 | 6.55e-04 | Male-biased |
| DLBC | ZBTB32 | VAV3 | 4.98e+00 | 9.92e-01 | 3.91e+00 | 4.46e-03 | Male-biased |
| DLBC | ZFHX3 | VAV3 | 5.07e+00 | 9.89e-01 | 4.17e+00 | 8.48e-03 | Male-biased |
| DLBC | ZNF232 | VAV3 | 4.15e+00 | 9.86e-01 | 2.85e+00 | 1.83e-03 | Male-biased |
| DLBC | ZNF418 | VAV3 | 4.18e+00 | 9.88e-01 | 1.16e+00 | 1.02e-05 | Male-biased |
| DLBC | ZNF433 | VAV3 | 4.22e+00 | 9.86e-01 | 3.09e+00 | 3.38e-03 | Male-biased |
| UVM | ZNF418 | VAV3 | 4.11e+00 | 1.20e-02 | 5.33e+00 | 9.84e-01 | Female-biased |
| VAV3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for VAV3 |
| RBPs related to ES in VAV3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| COAD | U2AF2 | exon_skip_28839 | 8.91e+00 | 1.32e-02 | 9.22e+00 | 9.83e-01 | Female-biased |
| KIRP | HNRNPH2 | exon_skip_28850 | 8.45e+00 | 9.91e-01 | 7.98e+00 | 2.44e-03 | Male-biased |
| KIRP | PTBP1 | exon_skip_28834 | 9.02e+00 | 9.85e-01 | 8.70e+00 | 1.03e-02 | Male-biased |
| BRCA | HNRNPH2 | exon_skip_28850 | 7.70e+00 | 6.22e-03 | 8.47e+00 | 9.87e-01 | Female-biased |
| KICH | PTBP1 | exon_skip_28834 | 8.93e+00 | 9.81e-01 | 8.64e+00 | 1.39e-02 | Male-biased |
| VAV3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000134215 | LINC02671,hsa-mir-499a,VAV3 | Tumor sex-biased ceRNA | TCGA-ACC |
| ENSG00000134215 | AC100861.1,hsa-mir-203a,VAV3 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000134215 | AC024075.1,hsa-mir-203a,VAV3 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000134215 | AC105339.2,hsa-mir-340,VAV3 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000134215 | KCNQ1OT1,hsa-mir-655,VAV3 | Female-specific ceRNA | TCGA-LIHC |
| ENSG00000134215 | LINC02803,hsa-mir-655,VAV3 | Female-specific ceRNA | TCGA-LIHC |
| ENSG00000134215 | Z95331.1,hsa-mir-655,VAV3 | Female-specific ceRNA | TCGA-LIHC |
| ENSG00000134215 | LINC00298,hsa-mir-211,VAV3 | Tumor sex-biased ceRNA | TCGA-SARC |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs35430228 | chr1:115449983:G:C | - | 0.112115835430144 | 0.0232577936032349 | LUSC | Female-baised eQTL |
| rs34774919 | chr1:115450253:G:A | - | 0.112115835430144 | 0.0232577936032349 | LUSC | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs114048919 | chr1:115587340:C:T | - | 0.179367503976816 | 0.0213707757414256 | READ | Male-baised eQTL |
| rs3010381 | chr1:115646511:T:G | - | 0.162419402283522 | 0.0368549370983417 | READ | Male-baised eQTL |
| rs12732821 | chr1:115033554:G:A | - | 0.109231346234775 | 0.00139407136239402 | LUAD | Male-baised eQTL |
| rs641227 | chr1:110497433:A:G | - | -0.0798835002321293 | 0.0232363126403196 | COAD | Male-baised eQTL |
| rs11164580 | chr1:102695717:G:A | - | 0.0751726016845607 | 0.0286554153740293 | COAD | Male-baised eQTL |
| rs10782902 | chr1:102698495:G:A | - | 0.0738833272766267 | 0.0331349677045062 | COAD | Male-baised eQTL |
| rs7527414 | chr1:102699725:A:G | - | 0.0738833272766267 | 0.0331349677045062 | COAD | Male-baised eQTL |
| rs720315 | chr1:102709493:T:A | - | 0.0738833272766267 | 0.0331349677045062 | COAD | Male-baised eQTL |
| rs12740872 | chr1:102718119:C:T | - | 0.0700502675595225 | 0.044523743890797 | COAD | Male-baised eQTL |
| rs561606 | chr1:110499303:G:A | - | -0.0699930814822781 | 0.048662137800964 | COAD | Male-baised eQTL |
| rs2138801 | chr1:102659496:C:T | - | 0.0701435334797226 | 0.0488450499419447 | COAD | Male-baised eQTL |
| rs10443190 | chr1:102687552:G:A | - | 0.0708321643009695 | 0.049535104974109 | COAD | Male-baised eQTL |
| rs1451031 | chr1:102729105:A:G | - | 0.0688608391232899 | 0.049898269978343 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000134215 |
| CpG Site: cg09896211 | |
| Position to Gene: gene | |
| Male Effect: -0.141911248092009 | |
| Female Effect: - | |
 | Gene ID: ENSG00000134215 |
| CpG Site: cg09896211 | |
| Position to Gene: gene | |
| Male Effect: -0.139368998501429 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg09896211 | chr1:107689799 | gene | -0.141911248092009 | 3.39772186262981e-10 | -0.466765910311186 | 4.958503100095405e-13 | LUAD |
| cg09896211 | chr1:107689799 | gene | -0.139368998501429 | 1.12285851489656e-05 | -0.3134244873481694 | 8.034510861955615e-08 | BLCA |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_28852 | chr1:107683487:107683533 | Frame-shift | rs11184955 | chr1:106656184:A:C | Distant downstream | -0.0228968459490957 | 0.0345684845133635 | COAD | Female-baised sQTL |
| exon_skip_28852 | chr1:107683487:107683533 | Frame-shift | rs12048938 | chr1:106652708:G:A | Distant downstream | -0.0228167055631036 | 0.0371895197119824 | COAD | Female-baised sQTL |
| exon_skip_28852 | chr1:107683487:107683533 | Frame-shift | rs4915093 | chr1:108029484:G:A | Distant upstream | -0.0683557194794731 | 0.0494290260511553 | KIRP | Female-baised sQTL |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| exon_skip_28852 | chr1:107683487:107683533 | Frame-shift | rs6583047 | chr1:107767670:A:C | Distant upstream | 0.0238300686515185 | 0.0140310645294296 | HNSC | Male-baised sQTL |
| exon_skip_28852 | chr1:107683487:107683533 | Frame-shift | rs6703924 | chr1:107764137:C:G | Distant upstream | 0.0205847695891627 | 0.0419424860596766 | HNSC | Male-baised sQTL |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of VAV3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000134215 | VAV3 | C0017661 | IGA Glomerulonephritis | 1 | CTD_human |
| ENSG00000134215 | VAV3 | C0020538 | Hypertensive disease | 1 | CTD_human |
| ENSG00000134215 | VAV3 | C0020578 | Hyperventilation | 1 | CTD_human |
| ENSG00000134215 | VAV3 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000134215 | VAV3 | C0039231 | Tachycardia | 1 | CTD_human |
| ENSG00000134215 | VAV3 | C0080203 | Tachyarrhythmia | 1 | CTD_human |
| ENSG00000134215 | VAV3 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
